Stocks Rise as "Fear Gauge" Cools Off

The World Health Organization calls omicron a "variant of concern"

Deputy Editor
Nov 29, 2021 at 11:54 AM
facebook twitter linkedin

The Dow Jones Industrial Average (DJI) and Nasdaq Composite (IXIC) are both up triple digits midday, paring some of their losses from Friday's massive selloff. The S&P 500 Index (SPX) is sitting in the black as well, as the world watches for updates on the Covid-19 omicron variant, which the World Health Organization (WHO) has called a "variant of concern."

Wall Street's "fear gauge," the Cboe Volatility Index (VIX), has cooled off from its Friday spike, last seen down 17%. Elsewhere, retailers are in focus amid "Cyber Monday" sales, while pending home sales rose 7.5% in October -- much higher than Wall Street's anticipated 0.7%. 

Continue reading for more on today's market, including: 

  • Eco-friendly footwear stock sees wave of fresh coverage. 
  • Zoom Video stock slumps despite renewed Covid-19 fears. 
  • Plus, LI options surge; KRYS doubles in value; and FENC plummets on FDA prediction.  

mmc Nov29

China-based electric vehicle name Li Auto Inc (NASDAQ:LI) is seeing a surge in options activity today. The company's upbeat third-quarter revenue comes after vehicle deliveries nearly tripled for the quarter, while Li Auto also raised its fourth-quarter forecast. So far, 35,000 calls and 11,000 puts have crossed the tape, which is five times the intraday average. The weekly 12/3 36-strike call is the most popular, followed by the 35-strike call in the same series, with new positions being opened at both. 

Soaring to the top of the Nasdaq today is Krystal Biotech Inc (NASDAQ:KRYS), up 114.9% at to trade at $85.56, after the company said its experimental topical drug, VYJUVEK, met the primary goal in a late-stage study for patients with dystrophic epidermolysis bullosa. To follow, Evercore ISI raised its price target to $125 from $100. Now trading at record highs, KRYS is up 44.3% year-to-date. 

Meanwhile, Fennec Pharmaceuticals Inc (NASDAQ:FENC) is taking a dive into penny stock territory, down 49.7% to trade at $4.85, after the company noted it doesn't expect the U.S. Food and Drug Administration (FDA) to approve its treatment for preventing chemotherapy-induced hearing loss in pediatric patients. Now at a new annual low, long-term support at the $5 level could prop up today's bear gap. 

FENC Nov29


Minimize Risk While Maximizing Profits

There is no options strategy like this one, which consistently minimizes risk while maintaining maximum profits. Perfect for traders looking for ways to control risk, reduce losses, and increase the likelihood of success when trading calls and puts. The Schaeffer’s team has over 41 years of options trading success targeting +100% gains on every trade. Rest assured your losses are effectively limited to your initial cost at the time of making your move! Don't waste another second... join us right now before the next trade is released! 



Special Offers from Schaeffer's Trading Partners